-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Press Center
Find Novavax’s press releases, statements and materials for journalists.
Dec 10, 2024
COVID-19,Seasonal influenza
In the News
See what others are saying about Novavax.
Note: This section features articles written by independent and external media outlets and journalists.


BiotechTV
After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline


Yahoo Finance
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Washington Business Journal
The turnaround man, John Jacobs is reshaping Novavax for the post-pandemic era

Media contact
Email: [email protected]
Phone: (202) 709-5563



Images, videos, and files for media use
Extensive materials for members of the press, including broadcast, online, film, radio and print journalists.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a global biotechnology company focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships